Velmanase alfa clinical trials
Also written Lamazym and rhLAMAN.
How each study uses velmanase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 16 Feb 2023 · LAMZEDE · BLA 761278 (FDA, Drugs@FDA)
- European Union
- 23 Mar 2018 · Lamzede · EMEA/H/C/003922 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses velmanase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Lamazym Aftercare Study FR Designed to Provide Treatment for French PatientsCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT01908712Written as LamazymHow we know
- Lamazym Aftercare StudyCompletedPhase 3Chiesi Farmaceutici S.p.A.NCT01908725Written as LamazymHow we know
- Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-MannosidosisCompletedPhase 2Chiesi Farmaceutici S.p.A.NCT02998879Written as Velmanase Alfa (e.g. Lamazym)How we know
- Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha MannosidosisWithdrawnPhase 3Chiesi Farmaceutici S.p.A.NCT04031066Written as Velmanase AlfaHow we know
- Evaluation of Long-term Efficacy of Treatment With LamazymCompletedPhase 3Zymenex A/SNCT02478840Written as LamazymHow we know
- Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisCompletedPhase 1Zymenex A/SNCT01268358Written as LamazymHow we know
- A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisCompletedPhase 3Zymenex A/SNCT01681953Written as LamazymHow we know
- Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-MannosidosisCompletedPhase 2Zymenex A/SNCT01681940Written as LamazymHow we know
- Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisStatus unknownPhase 2Zymenex A/SNCT01285700Written as LamazymHow we know
Codes
What other systems call velmanase alfa · ClinicalTrials.gg INT002164
- MeSH (NLM) C000731931velmanase-alfaOne source NLM
- UNII (FDA) M91TG242P2VELMANASE ALFAConfirmed FDA, NLM, Wikidata
- Wikidata Q98651803velmanase alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152849Velmanase AlfaOne source FDA
- DrugBank DB12374One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731931 | velmanase-alfa | One source NLM |
| UNII (FDA) | M91TG242P2 | VELMANASE ALFA | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q98651803 | velmanase alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152849 | Velmanase Alfa | One source FDA |
| DrugBank | DB12374 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.